Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Pharmacologic Suppression of Central Sympathetic Activity for Prevention of Atrial Fibrillation Recurrence After Pulmonary Vein Isolation (MOXAF)

NCT01791699 is registered in ClinicalTrials.gov with Spyridon Deftereos as lead sponsor.

NCT NCT01791699
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01791699 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Pharmacologic Suppression of Central Sympathetic Activity for Prevention of Atrial Fibrillation Recurrence After Pulmonary Vein Isolation (MOXAF)
Lead sponsor
Spyridon Deftereos
Phase
Phase 4
Overall status
Completed
Start date
August 31, 2012
Completion date
April 30, 2014
Enrollment
150 (estimated)
Sites
3

Conditions

As the registry lists them; a condition with its own page is linked.

atrial fibrillation